4//SEC Filing
Piacquad David 4
Accession 0000950170-25-022321
CIK 0001885522other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 4:30 PM ET
Size
12.7 KB
Accession
0000950170-25-022321
Insider Transaction Report
Form 4
Piacquad David
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−46,455→ 0 totalExercise: $17.00Exp: 2033-09-14→ Common Stock (46,455 underlying) - Award
Stock Option (Right to Buy)
2025-02-13+46,455→ 46,455 totalExercise: $1.69Exp: 2033-09-14→ Common Stock (46,455 underlying) - Award
Stock Option (Right to Buy)
2025-02-13+28,571→ 28,571 totalExercise: $1.69Exp: 2034-06-13→ Common Stock (28,571 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-13−28,571→ 0 totalExercise: $9.95Exp: 2034-06-13→ Common Stock (28,571 underlying)
Footnotes (4)
- [F1]1/36th of the shares subject to the option vest on each monthly anniversary measured from September 8, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
- [F2]On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
- [F3]100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
- [F4]Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
Documents
Issuer
Neumora Therapeutics, Inc.
CIK 0001885522
Entity typeother
Related Parties
1- filerCIK 0001602343
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 4:30 PM ET
- Size
- 12.7 KB